Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Burke, Carol A.
Samadder, N. Jewel
Funding for this research was provided by:
Cancer Prevention Pharmaceuticals, Inc.
unspecified valid from 2016-08-02